Alere Inc (ALR) 48.45 $ALR
Alere Up 15.7% Since SmarTrend Uptrend Call (ALR)
Comtex SmarTrend(R) - Wed Mar 18, 11:37AM CDT
SmarTrend identified an Uptrend for Alere (AMEX:ALR) on September 15th, 2014 at $41.94. In approximately 6 months, Alere has returned 15.70% as of today's recent price of $48.52.
ALR: 48.45 (+0.15)
Alere (ALR) Touches 52-Week High on Portfolio Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 12:00PM CDT
Shares of Alere Inc. (ALR) attained a new 52-week high of $49.47 on Mar 13, eventually closing lower at $49.06
ABAX: 65.61 (+1.33), ALR: 48.45 (+0.15), LMNX: 15.98 (-0.08), AFFX: 12.87 (-0.07)
Alere Has Returned 12.9% Since SmarTrend Recommendation (ALR)
Comtex SmarTrend(R) - Wed Mar 11, 10:14AM CDT
SmarTrend identified an Uptrend for Alere (AMEX:ALR) on September 15th, 2014 at $41.94. In approximately 6 months, Alere has returned 12.94% as of today's recent price of $47.36.
ALR: 48.45 (+0.15)
Chembio: Solid 2014, Future Looks Bright With New Products, Restocked Pipeline
Brian Marckx, CFA - at Seeking Alpha - Tue Mar 10, 1:49PM CDT
ALR: 48.45 (+0.15), CEMI: 4.20 (+0.05)
Alere Announces Chief Financial Officer Transition
PR Newswire - Mon Mar 09, 3:30PM CDT
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that David Teitel, the Company's Chief Financial Officer (CFO), will transition from the role of Chief Financial Officer when a suitable successor is hired.
ALR: 48.45 (+0.15)
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock
PR Newswire - Tue Mar 03, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.
. The dividend is payable on April 15, 2015 to holders of record of Series B stock at the close of business on April 1, 2015.
ALR: 48.45 (+0.15)
Alere Receives IVD CE Mark for Alere(TM) q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care
PR Newswire - Mon Mar 02, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced it has received IVD CE marking in Europe for the Alere q HIV-1/2 Detect assay, the first molecular diagnostic at the point of care (POC) that identifies HIV-1 and HIV-2 in less than 60 minutes. Molecular testing of HIV nucleic acids is required for acute detection as well as accurate Early Infant Diagnosis (EID). Current antibody POC tests cannot discriminate between a mother's and infant's antibodies to detect if a newborn has become infected with HIV.
ALR: 48.45 (+0.15)
Alere (ALR) Disappoints; Misses on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:44AM CST
Alere Inc. (ALR) reported disappointing fourth-quarter 2014 results with both its top and bottom line missing the Zacks Consensus Estimate.
ABMD: 60.00 (-1.10), INGN: 32.05 (-0.10), ALR: 48.45 (+0.15), SURG: 5.21 (-0.02)
Alere's (ALR) CEO Namal Nawana on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:07PM CST
ALR: 48.45 (+0.15)
Alere misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:02AM CST
ALR: 48.45 (+0.15)
Alere Inc. Announces Fourth Quarter 2014 Results
PR Newswire - Tue Feb 10, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014.
ALR: 48.45 (+0.15)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:30PM CST
WYN: 92.12 (+0.59), TLM: 7.61 (-0.04), CYNO: 30.79 (+0.33), PCG: 53.96 (+0.35), KKR: 23.12 (+0.31), GWR: 103.58 (-0.23), CDW: 37.77 (+0.45), ALLT: 9.38 (+0.02), HOT: 84.39 (+0.89), SAVE: 79.79 (-0.16), NSP: 54.38 (-0.14), MWW: 6.51 (+0.04), ACM: 31.09 (+0.88), DF: 16.16 (+0.29), REGN: 488.87 (+2.85), KO: 40.65 (+0.63), MLM: 138.50 (-0.18), RAI: 69.90 (+0.33), HCP: 42.44 (+1.20), SEE: 46.72 (+0.19), ENTG: 13.59 (+0.14), TAP: 74.57 (+1.42), ALR: 48.45 (+0.15), HNT: 61.31 (+0.11), OMC: 78.31 (+0.08), IMN: 3.94 (-0.20), SALE: 17.93 (+0.66), NILE: 31.08 (+0.64), CVS: 103.86 (+0.52), SFUN: 5.68 (+0.01)
Will Alere (ALR) Surprise Earnings Estimates This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 9:04AM CST
Alere Inc. (ALR) is set to report fourth-quarter 2014 results on Feb 10.
ACT: 317.06 (+2.65), ALNY: 117.46 (-2.24), UNH: 119.14 (-1.62), ALR: 48.45 (+0.15)
Alere Schedules Fourth Quarter 2014 Earnings Conference Call
PR Newswire - Tue Feb 03, 4:55PM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that it will release its financial results for the fourth quarter, ended December 31, 2014. The Company will host a conference call beginning at 8:30 a.m. ET on Tuesday, February 10, 2015, to discuss these results and provide business updates.
ALR: 48.45 (+0.15)
Chembio Acquires Rights to SURE CHECK(R) HIV 1/2 Assay Effective June 1, 2016
GlobeNewswire - Thu Jan 22, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK HIV 1/2 Assay, effective June 1, 2016.
ALR: 48.45 (+0.15), CEMI: 4.20 (+0.05)
Chembio to own full rights to HIV 1/2 test by mid-2016
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:59AM CST
ALR: 48.45 (+0.15), CEMI: 4.20 (+0.05)
Health Care Supplies Stocks Technical Review - Cerus, Unilife, DENTSPLY Intl., Alere, and Align Technology
PR Newswire - Thu Jan 22, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Unilife Corporation (NASDAQ: UNIS), DENTSPLY International Inc. (NASDAQ: XRAY), Alere Inc. (NYSE: ALR), and Align Technology Inc. (NASDAQ: ALGN). Free research report on Cerus can be accessed at http://get.Investor-Edge.com/pdf/?c=Cerus&...amp;s=CERS. On Wednesday, January 21, 2015, the NASDAQ Composite ended at 4,667.42, up 0.27%, the Dow Jones Industrial Average advanced 0.22%, to finish the day at 17,554.28, and the S&P 500 closed at 2,032.12, up 0.47%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index also advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
CERS: 4.29 (-0.05), ALGN: 57.18 (-1.14), UNIS: 3.63 (-0.01), ALR: 48.45 (+0.15), XRAY: 51.80 (-0.14)
Global Breath Analyzers Market 2014-2019 - Technology, by Application, by End User Analysis of the $1.53 Billion Industry
M2 - Mon Jan 19, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/9nfpk8/breath_analyzers) has announced the addition of the "Breath Analyzers Market by Technology, by Application, by End User - Analysis & Global Forecast to 2019" report to their offering. This market is expected to reach $1.53 billion in 2019 from $479.3 million in 2014 at a CAGR of 26.3% The breath analyzers market is categorized into four broad segments, namely, technology, applications, end users, and regions. The market, by technology, comprises fuel cell technology, semiconductor oxide sensor technology, and others. In 2014, the fuel cell technology segment accounted for the major share of the global market, by technology. Alcohol detection accounted for the largest share of the global market by application. Increasing alcohol and drug abuse, stringent government laws and regulations, an increase in the number of approvals from regulatory bodies, growing prominence of smartphone-based breath analyzers, and innovative product offerings (especially for medical applications) have stimulated the adoption of breath analyzers in the industry. However, in spite of numerous benefits, certain challenges such as inaccuracy and hygiene concerns are restraining the growth of this market. On the basis of end users, the breath analyzers market is segmented by law enforcement agencies, enterprises and individuals. Law enforcement agencies accounted for the largest share of the global market. Based on region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Africa, and Latin America) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Dynamics 6 Industry Trends 7 Breath Analyzers Market, By Technology 8 Breath Analyzers Market, By Application 9 Breath Analyzers Market, By End User 10 Breath Analyzers Market, By Geography 11 Competitive Landscape 12 Company Profiles - AK GlobalTech Corporation - Akers Biosciences, Inc. - Alcohol Countermeasure Systems Corporation - Alere, Inc. - BACtrack, Inc. - Dr?gerwerk AG & Co. KGaA - EnviteC-Wismar GmbH (A Honeywell Company) - Intoximeters, Inc. - Lifeloc Technologies - Mpd, Inc. - Quest Products, Inc. For more information visit http://www.researchandmarkets.com/research/9n..._analyzers
ALR: 48.45 (+0.15)
Global Infectious Disease Diagnostics Market 2014-2019 - Product, Application, Technology & End User Analysis of the $18 Billion Industry
M2 - Mon Jan 19, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vljzx/infectious) has announced the addition of the "Infectious Disease Diagnostics Market by Product, Application, Technology, End User - Global Forecast to 2019" report to their offering. The infectious disease diagnostics market is expected to grow at CAGR of 7.9% to reach $18.15 billion by 2019 from $12.42 billion in 2014 Increasing Prevalence of Deadly Infectious Disease and Need For Highly Specific and Sensitive Technologies for Rapid Diagnosis to Drive Growth of the IDD Market The immunodiagnostics and polymerase chain reaction technology segments accounted for the lion's share of the global IDD market by technology, owing to growing need for advanced technologies for rapid diagnosis of infectious diseases. On the basis of application, the IDD market is categorized into the Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue, among others). Hospital-acquired MRSA infections, human papillomavirus, and AIDS are expected to be new revenue pockets in the applications market. The rising prevalence of these diseases globally is the major factor driving the growth of the aforementioned markets. On the basis of product, the IDD market is segmented into instruments, consumables (reagents and assays), and software & services. Among products, consumables are estimated to be the fastest-growing market owing to its growing adoption in emerging infectious disease diagnostics worldwide. On the basis of end user, the market is segmented into hospital laboratories, reference labs, physician's office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing). Hospital laboratories are expected to be the fastest-growing market in the forecast period. Owing to the complexity and highly specialized nature of diagnostic tests for infectious diseases, hospital laboratories are expected to grow at the fastest rate in the forecast period, from 2014 to 2019. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Infectious Disease Diagnostics Market, By Product 8 Infectious Disease Diagnostics Market, By Application 9 Infectious Disease Diagnostics Market, By Technique 10 Infectious Disease Diagnostics Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Abbott Laboratories - Alere, Inc. - Becton, Dickinson & Co. - Bio-Rad Laboratories - Biom?rieux - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8vljzx/infectious
JNJ: 102.40 (+0.71), ABT: 47.47 (+0.03), BDX: 144.72 (-0.21), DHR: 87.15 (+0.14), ALR: 48.45 (+0.15)
Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019
M2 - Fri Jan 16, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/cl7fxt/microbiology) has announced the addition of the "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019" report to their offering. The global clinical microbiology market is expected to reach $12,411.36 million in 2019 at a CAGR of 13.03% between 2014 and 2019. Clinical microbiology consists of a wide array of techniques for the detection of infectious diseases. The respiratory diseases segment accounted for the largest application segment of the clinical microbiology market in 2014. According to the WHO, in 2012, there were about 450,000 new cases of multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 92 countries. Furthermore, the outbreak of new diseases such as Ebola is expected to increase the disease burden and the demand for clinical microbiology products. The microbiology market is segmented on the basis of applications into clinical, energy, environment, food, manufacturing, and pharmaceuticals. The food application segment is expected to grow at the highest CAGR between 2014 and 2019 however, the pharmaceuticals application segment accounted for the largest share of the microbiology market in 2014. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. The clinical microbiology consumables market is further bifurcated into kits and reagents, whereas the instruments market is sub segmented into automated microbiology instruments, laboratory instruments, and microbiology analyzers. The microbiology analyzers are further categorized into mass spectrometers, microscopes, and molecular diagnostics instruments. The laboratory instruments are further categorized into anaerobic gas systems, automated gram strainers, automated petri dish fillers, autoclave sterilizers, bacterial colony counters, incubators, microbial air samplers, and other laboratory instruments. Clinical microbiology finds applications in a large number of disease diagnosis. The clinical microbiology market on the basis of applications are segmented into bloodstream infections, gastrointestinal diseases, periodontal diseases, respiratory diseases, sexually transmitted diseases, urinary tract infections, and other diseases. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Microbiology Market, By Applications 8 Clinical Microbiology Market, By Product 9 Clinical Microbiology Market, By Applications 10 Clinical Microbiology Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Biom?rieux SA - Bruker Corporation - Cepheid - Danaher Corporation - F. Hoffmann-LA Roche Ltd. - Hologic, Inc. - Siemens AG For more information visit http://www.researchandmarkets.com/research/cl...crobiology
ABT: 47.47 (+0.03), CPHD: 58.39 (-1.13), DHR: 87.15 (+0.14), ALR: 48.45 (+0.15), HOLX: 33.26 (+0.28)
Alere Up 15.7% Since SmarTrend Uptrend Call (ALR)
Comtex SmarTrend(R) - Wed Mar 18, 11:37AM CDT
SmarTrend identified an Uptrend for Alere (AMEX:ALR) on September 15th, 2014 at $41.94. In approximately 6 months, Alere has returned 15.70% as of today's recent price of $48.52.
ALR: 48.45 (+0.15)
Alere (ALR) Touches 52-Week High on Portfolio Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 12:00PM CDT
Shares of Alere Inc. (ALR) attained a new 52-week high of $49.47 on Mar 13, eventually closing lower at $49.06
ABAX: 65.61 (+1.33), ALR: 48.45 (+0.15), LMNX: 15.98 (-0.08), AFFX: 12.87 (-0.07)
Alere Has Returned 12.9% Since SmarTrend Recommendation (ALR)
Comtex SmarTrend(R) - Wed Mar 11, 10:14AM CDT
SmarTrend identified an Uptrend for Alere (AMEX:ALR) on September 15th, 2014 at $41.94. In approximately 6 months, Alere has returned 12.94% as of today's recent price of $47.36.
ALR: 48.45 (+0.15)
Chembio: Solid 2014, Future Looks Bright With New Products, Restocked Pipeline
Brian Marckx, CFA - at Seeking Alpha - Tue Mar 10, 1:49PM CDT
ALR: 48.45 (+0.15), CEMI: 4.20 (+0.05)
Alere Announces Chief Financial Officer Transition
PR Newswire - Mon Mar 09, 3:30PM CDT
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that David Teitel, the Company's Chief Financial Officer (CFO), will transition from the role of Chief Financial Officer when a suitable successor is hired.
ALR: 48.45 (+0.15)
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock
PR Newswire - Tue Mar 03, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.
. The dividend is payable on April 15, 2015 to holders of record of Series B stock at the close of business on April 1, 2015. ALR: 48.45 (+0.15)
Alere Receives IVD CE Mark for Alere(TM) q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care
PR Newswire - Mon Mar 02, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced it has received IVD CE marking in Europe for the Alere q HIV-1/2 Detect assay, the first molecular diagnostic at the point of care (POC) that identifies HIV-1 and HIV-2 in less than 60 minutes. Molecular testing of HIV nucleic acids is required for acute detection as well as accurate Early Infant Diagnosis (EID). Current antibody POC tests cannot discriminate between a mother's and infant's antibodies to detect if a newborn has become infected with HIV.
ALR: 48.45 (+0.15)
Alere (ALR) Disappoints; Misses on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:44AM CST
Alere Inc. (ALR) reported disappointing fourth-quarter 2014 results with both its top and bottom line missing the Zacks Consensus Estimate.
ABMD: 60.00 (-1.10), INGN: 32.05 (-0.10), ALR: 48.45 (+0.15), SURG: 5.21 (-0.02)
Alere's (ALR) CEO Namal Nawana on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:07PM CST
ALR: 48.45 (+0.15)
Alere misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:02AM CST
ALR: 48.45 (+0.15)
Alere Inc. Announces Fourth Quarter 2014 Results
PR Newswire - Tue Feb 10, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014.
ALR: 48.45 (+0.15)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:30PM CST
WYN: 92.12 (+0.59), TLM: 7.61 (-0.04), CYNO: 30.79 (+0.33), PCG: 53.96 (+0.35), KKR: 23.12 (+0.31), GWR: 103.58 (-0.23), CDW: 37.77 (+0.45), ALLT: 9.38 (+0.02), HOT: 84.39 (+0.89), SAVE: 79.79 (-0.16), NSP: 54.38 (-0.14), MWW: 6.51 (+0.04), ACM: 31.09 (+0.88), DF: 16.16 (+0.29), REGN: 488.87 (+2.85), KO: 40.65 (+0.63), MLM: 138.50 (-0.18), RAI: 69.90 (+0.33), HCP: 42.44 (+1.20), SEE: 46.72 (+0.19), ENTG: 13.59 (+0.14), TAP: 74.57 (+1.42), ALR: 48.45 (+0.15), HNT: 61.31 (+0.11), OMC: 78.31 (+0.08), IMN: 3.94 (-0.20), SALE: 17.93 (+0.66), NILE: 31.08 (+0.64), CVS: 103.86 (+0.52), SFUN: 5.68 (+0.01)
Will Alere (ALR) Surprise Earnings Estimates This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 9:04AM CST
Alere Inc. (ALR) is set to report fourth-quarter 2014 results on Feb 10.
ACT: 317.06 (+2.65), ALNY: 117.46 (-2.24), UNH: 119.14 (-1.62), ALR: 48.45 (+0.15)
Alere Schedules Fourth Quarter 2014 Earnings Conference Call
PR Newswire - Tue Feb 03, 4:55PM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that it will release its financial results for the fourth quarter, ended December 31, 2014. The Company will host a conference call beginning at 8:30 a.m. ET on Tuesday, February 10, 2015, to discuss these results and provide business updates.
ALR: 48.45 (+0.15)
Chembio Acquires Rights to SURE CHECK(R) HIV 1/2 Assay Effective June 1, 2016
GlobeNewswire - Thu Jan 22, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK HIV 1/2 Assay, effective June 1, 2016.
ALR: 48.45 (+0.15), CEMI: 4.20 (+0.05)
Chembio to own full rights to HIV 1/2 test by mid-2016
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:59AM CST
ALR: 48.45 (+0.15), CEMI: 4.20 (+0.05)
Health Care Supplies Stocks Technical Review - Cerus, Unilife, DENTSPLY Intl., Alere, and Align Technology
PR Newswire - Thu Jan 22, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Unilife Corporation (NASDAQ: UNIS), DENTSPLY International Inc. (NASDAQ: XRAY), Alere Inc. (NYSE: ALR), and Align Technology Inc. (NASDAQ: ALGN). Free research report on Cerus can be accessed at http://get.Investor-Edge.com/pdf/?c=Cerus&...amp;s=CERS. On Wednesday, January 21, 2015, the NASDAQ Composite ended at 4,667.42, up 0.27%, the Dow Jones Industrial Average advanced 0.22%, to finish the day at 17,554.28, and the S&P 500 closed at 2,032.12, up 0.47%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index also advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
CERS: 4.29 (-0.05), ALGN: 57.18 (-1.14), UNIS: 3.63 (-0.01), ALR: 48.45 (+0.15), XRAY: 51.80 (-0.14)
Global Breath Analyzers Market 2014-2019 - Technology, by Application, by End User Analysis of the $1.53 Billion Industry
M2 - Mon Jan 19, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/9nfpk8/breath_analyzers) has announced the addition of the "Breath Analyzers Market by Technology, by Application, by End User - Analysis & Global Forecast to 2019" report to their offering. This market is expected to reach $1.53 billion in 2019 from $479.3 million in 2014 at a CAGR of 26.3% The breath analyzers market is categorized into four broad segments, namely, technology, applications, end users, and regions. The market, by technology, comprises fuel cell technology, semiconductor oxide sensor technology, and others. In 2014, the fuel cell technology segment accounted for the major share of the global market, by technology. Alcohol detection accounted for the largest share of the global market by application. Increasing alcohol and drug abuse, stringent government laws and regulations, an increase in the number of approvals from regulatory bodies, growing prominence of smartphone-based breath analyzers, and innovative product offerings (especially for medical applications) have stimulated the adoption of breath analyzers in the industry. However, in spite of numerous benefits, certain challenges such as inaccuracy and hygiene concerns are restraining the growth of this market. On the basis of end users, the breath analyzers market is segmented by law enforcement agencies, enterprises and individuals. Law enforcement agencies accounted for the largest share of the global market. Based on region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Africa, and Latin America) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Dynamics 6 Industry Trends 7 Breath Analyzers Market, By Technology 8 Breath Analyzers Market, By Application 9 Breath Analyzers Market, By End User 10 Breath Analyzers Market, By Geography 11 Competitive Landscape 12 Company Profiles - AK GlobalTech Corporation - Akers Biosciences, Inc. - Alcohol Countermeasure Systems Corporation - Alere, Inc. - BACtrack, Inc. - Dr?gerwerk AG & Co. KGaA - EnviteC-Wismar GmbH (A Honeywell Company) - Intoximeters, Inc. - Lifeloc Technologies - Mpd, Inc. - Quest Products, Inc. For more information visit http://www.researchandmarkets.com/research/9n..._analyzers
ALR: 48.45 (+0.15)
Global Infectious Disease Diagnostics Market 2014-2019 - Product, Application, Technology & End User Analysis of the $18 Billion Industry
M2 - Mon Jan 19, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vljzx/infectious) has announced the addition of the "Infectious Disease Diagnostics Market by Product, Application, Technology, End User - Global Forecast to 2019" report to their offering. The infectious disease diagnostics market is expected to grow at CAGR of 7.9% to reach $18.15 billion by 2019 from $12.42 billion in 2014 Increasing Prevalence of Deadly Infectious Disease and Need For Highly Specific and Sensitive Technologies for Rapid Diagnosis to Drive Growth of the IDD Market The immunodiagnostics and polymerase chain reaction technology segments accounted for the lion's share of the global IDD market by technology, owing to growing need for advanced technologies for rapid diagnosis of infectious diseases. On the basis of application, the IDD market is categorized into the Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue, among others). Hospital-acquired MRSA infections, human papillomavirus, and AIDS are expected to be new revenue pockets in the applications market. The rising prevalence of these diseases globally is the major factor driving the growth of the aforementioned markets. On the basis of product, the IDD market is segmented into instruments, consumables (reagents and assays), and software & services. Among products, consumables are estimated to be the fastest-growing market owing to its growing adoption in emerging infectious disease diagnostics worldwide. On the basis of end user, the market is segmented into hospital laboratories, reference labs, physician's office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing). Hospital laboratories are expected to be the fastest-growing market in the forecast period. Owing to the complexity and highly specialized nature of diagnostic tests for infectious diseases, hospital laboratories are expected to grow at the fastest rate in the forecast period, from 2014 to 2019. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Infectious Disease Diagnostics Market, By Product 8 Infectious Disease Diagnostics Market, By Application 9 Infectious Disease Diagnostics Market, By Technique 10 Infectious Disease Diagnostics Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Abbott Laboratories - Alere, Inc. - Becton, Dickinson & Co. - Bio-Rad Laboratories - Biom?rieux - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8vljzx/infectious
JNJ: 102.40 (+0.71), ABT: 47.47 (+0.03), BDX: 144.72 (-0.21), DHR: 87.15 (+0.14), ALR: 48.45 (+0.15)
Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019
M2 - Fri Jan 16, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/cl7fxt/microbiology) has announced the addition of the "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019" report to their offering. The global clinical microbiology market is expected to reach $12,411.36 million in 2019 at a CAGR of 13.03% between 2014 and 2019. Clinical microbiology consists of a wide array of techniques for the detection of infectious diseases. The respiratory diseases segment accounted for the largest application segment of the clinical microbiology market in 2014. According to the WHO, in 2012, there were about 450,000 new cases of multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 92 countries. Furthermore, the outbreak of new diseases such as Ebola is expected to increase the disease burden and the demand for clinical microbiology products. The microbiology market is segmented on the basis of applications into clinical, energy, environment, food, manufacturing, and pharmaceuticals. The food application segment is expected to grow at the highest CAGR between 2014 and 2019 however, the pharmaceuticals application segment accounted for the largest share of the microbiology market in 2014. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. The clinical microbiology consumables market is further bifurcated into kits and reagents, whereas the instruments market is sub segmented into automated microbiology instruments, laboratory instruments, and microbiology analyzers. The microbiology analyzers are further categorized into mass spectrometers, microscopes, and molecular diagnostics instruments. The laboratory instruments are further categorized into anaerobic gas systems, automated gram strainers, automated petri dish fillers, autoclave sterilizers, bacterial colony counters, incubators, microbial air samplers, and other laboratory instruments. Clinical microbiology finds applications in a large number of disease diagnosis. The clinical microbiology market on the basis of applications are segmented into bloodstream infections, gastrointestinal diseases, periodontal diseases, respiratory diseases, sexually transmitted diseases, urinary tract infections, and other diseases. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Microbiology Market, By Applications 8 Clinical Microbiology Market, By Product 9 Clinical Microbiology Market, By Applications 10 Clinical Microbiology Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Biom?rieux SA - Bruker Corporation - Cepheid - Danaher Corporation - F. Hoffmann-LA Roche Ltd. - Hologic, Inc. - Siemens AG For more information visit http://www.researchandmarkets.com/research/cl...crobiology
ABT: 47.47 (+0.03), CPHD: 58.39 (-1.13), DHR: 87.15 (+0.14), ALR: 48.45 (+0.15), HOLX: 33.26 (+0.28)
